Lv61
1950 积分 2023-11-20 加入
Evolving roles of MET as a therapeutic target in NSCLC and beyond
1小时前
待确认
1004P Subsequent therapy and outcomes after first-line alectinib in Asian patients with ALK-positive (ALK+) non-small cell lung cancer (NSCLC): A post-hoc analysis of the ALESIA study
5小时前
已关闭
A case of lung adenocarcinoma with MET∆ex14 mutation regressed after preoperative treatment with savolitinib, and successfully underwent radical resection
1个月前
已完结
A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites
1个月前
已完结
Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal–epithelial transition exon 14 skipping mutation: a case report and literature review
1个月前
已完结
Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report
1个月前
已完结
A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites
1个月前
已完结
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies
3个月前
已完结
Leptomeningeal metastases in non-small-cell lung cancer
3个月前
已完结
A Multicenter Study of Hereditary Transthyretin Amyloidosis in China
5个月前
已完结
皖公网安备34019202002308
